Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Chief Commercial Officer | January 20, 2025 | January 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date January 20, 2025 · Filed January 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,069 |
Reported balance
After 2025-01-20 transaction · row 1
1 source rowRow 1 · 2025-01-20 · Tax withholding · Disposed 4,858 · Balance 82,069 F1: Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2025 Filed Jan 23, 2025 00:49 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 4,858 | $1.39 | $6,752.62 |
DisclosureSEC source: 0001610717-25-000014 · form4.xml · nonDerivative · entry 1 Reider Paul · CIK 0001970033 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,069 F1 · shares: Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. Read SEC document |
| January 04, 2025 Filed Jan 8, 2025 01:50 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 2,277 | $1.66 | $3,779.82 |
DisclosureSEC source: 0001610717-25-000007 · form4.xml · nonDerivative · entry 1 Reider Paul · CIK 0001970033 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,927 F1 · shares: Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. Read SEC document |
| January 03, 2025 Filed Jan 8, 2025 01:50 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001610717-25-000007 · form4.xml · derivative · entry 2 Reider Paul · CIK 0001970033 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2035-01-03 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 3, 2025 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 21:44 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 2,073 | $1.61 | $3,337.53 |
DisclosureSEC source: 0001610717-24-000542 · form4.xml · nonDerivative · entry 1 Reider Paul · CIK 0001970033 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,204 F1 · shares: Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. F2 · balance_after: Includes 5,000 shares acquired on November 15, 2024 and 5,000 shares acquired on May 15, 2024, each pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| July 22, 2024 Filed Jul 25, 2024 00:14 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001610717-24-000405 · form4.xml · derivative · entry 1 Reider Paul · CIK 0001970033 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-04-11 F1 · derivative.exercise_date: On April 11, 2024 the Reporting Person was granted a performance stock option to purchase 200,000 shares of common stock, of which 40,000 of the shares vested and became exercisable on July 22, 2024 in connection with the Closing of the sale of Coherus BioSciences, Inc.'s YUSIMRY franchise. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 01:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 4,854 | $2.44 | $11,843.76 |
DisclosureSEC source: 0001610717-24-000038 · form4.xml · nonDerivative · entry 1 Reider Paul · CIK 0001970033 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,277 F1 · shares: Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 23:58 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 2,275 | $2.92 | $6,643.00 |
DisclosureSEC source: 0001610717-24-000018 · form4.xml · nonDerivative · entry 1 Reider Paul · CIK 0001970033 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,131 F1 · shares: Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:13 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001610717-24-000011 · form4.xml · derivative · entry 1 Reider Paul · CIK 0001970033 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2034-01-02 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to the option shall vest in successive, equal monthly installments measured from January 2, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 21:47 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 2,049 | $2.37 | $4,856.13 |
DisclosureSEC source: 0001610717-23-000401 · form4.xml · nonDerivative · entry 1 Reider Paul · CIK 0001970033 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,406 F1 · shares: Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. F2 · balance_after: Includes 3,402 shares acquired on May 15, 2023 pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001610717-23-000165 · form4.xml · derivative · entry 1 Reider Paul · CIK 0001970033 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 50% of the shares on each anniversary measured from June 13, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:57 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 2,451 | $6.84 | $16,764.84 |
DisclosureSEC source: 0001140361-23-016454 · form4.xml · nonDerivative · entry 1 Reider Paul · CIK 0001970033 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,053 F1 · shares: Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.